Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading

To compare histological feature of prostate cancer (PCa) according androgenic status in patients who underwent radical prostatectomy (RP).

Between March 2007 and September 2013, we prospectively analysed 937 patients who were referred to our centre for RP.

Clinical, pathological and biological data have been prospectively collected. Preoperative total testosterone (TT) and bioavailable testosterone (BT) serum determinations were carried out. The threshold for low serum testosterone was set at TT

Nine hundred and thirty-seven consecutive patients were included. In all, 14. 9% patients had low TT in the population. An exact match between biopsy and prostate specimens in GS grading was observed for 50. 6% patients (n=474). Also, 40. 9% of all patients were upgraded (n=383): 45. 3% (n=63) in low serum testosterone patients and 40. 1% (n=320) in normal serum testosterone patients. For prostate specimens, the proportion of patients with predominant Gleason pattern 4 was higher in patients with low TT compared with normal TT (41. 7% vs 29. 1%, P=0. 0029). In all, 20. 1% were upgraded from predominant Gleason pattern 3 on biopsies specimen to predominant Gleason 4 pattern on the prostate specimen in patients with low TT, whereas 11. 6% were upgraded for normal TT patients (P=0. 002).

Low serum testosterone is an independent risk factor for predominant Gleason pattern 4 on prostate specimen after RP and for upgrading from low- to high-grade cancer between prostate needle biopsies and RP specimen. This observation should be taken into account in localised PCa management, especially for active surveillance or when a nerve-sparing approach is considered. Prostate Cancer and Prostatic Diseases advance online publication, 6 October 2015; doi:10. 1038/pcan. 2015. 44.

Prostate cancer and prostatic diseases. 2015 Oct 06 [Epub ahead of print]

A Pichon, Y Neuzillet, H Botto, J-P Raynaud, C Radulescu, V Molinié, J-M Herve, T Lebret

Department of Urology, Foch Hospital, Suresnes, France. , Department of Urology, Foch Hospital, Suresnes, France. , Department of Urology, Foch Hospital, Suresnes, France. , Department of Physiology, University Pierre and Marie Curie, Paris, France. , Department of Pathology, Foch Hospital, Suresnes, France. , Department of Pathology, CHU de Fort-de-France, Fort-de-France, France. , Department of Urology, Foch Hospital, Suresnes, France. , Department of Urology, Foch Hospital, Suresnes, France.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe